← All trials
NCT05827549
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 4, 2024
- Primary completion
- Dec 31, 2032
- Completion date
- Dec 31, 2032
- First posted
- Apr 25, 2023
- Last posted
- Jun 6, 2025
- Enrollment
- 90
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UlsanLead sponsor
- Seoul National UniversityCollaborator
- University of UlsanSponsor investigator
- Chonnam National UniversityCollaborator
- Catholic University of KoreaCollaborator
- Sungkyunkwan UniversityCollaborator
- Pusan National UniversityCollaborator
- University of UlsanOfficial
- Yonsei UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.